Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$17.1 - $22.26 $1.85 Million - $2.41 Million
-108,427 Reduced 83.78%
20,992 $454,000
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $1.82 Million - $5.32 Million
108,596 Added 521.52%
129,419 $2.66 Million
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $846,454 - $1.24 Million
20,823 New
20,823 $979,000
Q4 2022

Feb 14, 2023

BUY
$32.2 - $43.61 $182,509 - $247,181
5,668 Added 61.58%
14,872 $567,000
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $297,105 - $398,257
9,204 New
9,204 $360,000
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $459,033 - $633,673
-16,680 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $512,242 - $762,442
16,680 New
16,680 $552,000
Q2 2021

Aug 16, 2021

SELL
$54.88 - $79.29 $841,475 - $1.22 Million
-15,333 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$70.65 - $96.76 $1.08 Million - $1.48 Million
15,333 New
15,333 $1.15 Million
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $824,656 - $1.25 Million
-20,050 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $321,286 - $534,240
12,381 Added 161.44%
20,050 $834,000
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $107,502 - $317,533
4,111 Added 115.54%
7,669 $220,000
Q4 2019

Feb 14, 2020

SELL
$60.18 - $154.77 $772,831 - $1.99 Million
-12,842 Reduced 78.3%
3,558 $257,000
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $2.3 Million - $3.12 Million
16,400 New
16,400 $2.3 Million
Q4 2018

Feb 14, 2019

SELL
$81.94 - $139.71 $729,266 - $1.24 Million
-8,900 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$138.11 - $169.04 $1.23 Million - $1.5 Million
8,900 New
8,900 $1.26 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $641M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.